Cover Image

Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease

Oncogene addiction in non-small-cell lung cancer (NSCLC) has profound diagnostic and therapeutic implications. ALK, ROS1 and NTRK rearrangements are found in about 2-7%, 1-2% and 0.2% of unselected NSCLC samples, respectively; however, their frequency is markedly higher in younger and never-smoker p...

Full description

Saved in:

Bibliographic Details
Main Authors:	Daniele Marinelli (Author), Marco Siringo (Author), Giulio Metro (Author), Biagio Ricciuti (Author), Alain J Gelibter (Author)
Format:	Book
Published:	BioExcel Publishing Ltd, 2022-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease
by: Giulio Metro, et al.
Published: (2022)

The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks
by: Andrea De Giglio, et al.
Published: (2023)

Non-small-cell lung cancer: how to manage RET-positive disease
by: Elisa Andrini, et al.
Published: (2022)

Non-small-cell lung cancer: how to manage EGFR-mutated disease
by: Federica Pecci, et al.
Published: (2022)

Identification and therapeutic evaluation of ALK rearrangements in non‐small‐cell lung cancer
by: Ruiying Zhao, et al.
Published: (2022)

Case report: Concomitant EGFR mutation and ALK rearrangement in non-small cell lung cancer
by: Haoyue Hu, et al.
Published: (2023)

Advanced non-small-cell lung cancer: how to manage non-oncogene disease Andrea De Giglio, Alessandro Di Federico, Chiara De
by: Andrea De Giglio, et al.
Published: (2022)

First-line alectinib for ALK-positive lung cancer: is there room for further improvement?
by: Alfredo Addeo, et al.
Published: (2018)

Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
by: Liu D, et al.
Published: (2018)

Detection of ALK Gene Rearrangements in Non-Small Cell Lung Cancer by Immunocytochemistry and Fluorescence in Situ Hybridization on Cytologic Samples
by: Suneel RACHAGIRI, et al.
Published: (2022)

How to manage KRAS G12C-mutated advanced non-small-cell lung cancer
by: Biagio Ricciuti, et al.
Published: (2022)

Diagnosis and Treatment of Advanced ALK Rearrangement-Positive Non-Small-Cell Lung Cancer in Portugal: Results of a National Questionnaire
by: Ana Figueiredo, et al.
Published: (2023)

Concomitant EGFR mutation and ALK rearrangement in multifocal lung adenocarcinoma: a case report
by: Jun Fan, et al.
Published: (2020)

ALK rearrangement: a high-frequency alteration in ovarian metastasis from lung adenocarcinoma
by: Rui Bi, et al.
Published: (2019)

TMP3-NTRK1 rearranged uterine sarcoma: A case report
by: William Boyle, et al.
Published: (2020)

Primary resistance to first- and second-generation ALK inhibitors in a non-small cell lung cancer patient with coexisting ALK rearrangement and an ALK F1174L-cis-S1189C de novo mutation: A case report
by: Jiuzhou Zhao, et al.
Published: (2022)

A case of thyroid carcinoma with mucinous features harboring ETV6-NTRK3 fusion: Expanding the morphologic spectrum of NTRK-rearranged thyroid carcinoma
by: Khaled A. Murshed, et al.
Published: (2022)

Population pharmacokinetics and exposure-response analyses of SAF-189s in Chinese patients with ALK+/ROS1+ non-small cell lung cancer
by: Yinhui Liu, et al.
Published: (2024)

ALK, ROS1 and EGFR status of lung cancers in the Aegean Region of Turkey
by: Gulden Diniz, et al.
Published: (2022)

Later-Line Treatment with Lorlatinib in <i>ALK</i>- and <i>ROS1</i>-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis
by: Maximilian J. Hochmair, et al.
Published: (2020)

Conservative surgical treatment with fertility preservation in a young adult with NTRK rearranged spindle cell neoplasm of the uterine cervix
by: Marco M. Bühler, et al.
Published: (2023)

Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer
by: David M. Waterhouse, et al.
Published: (2020)

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer
by: Valerio Gristina, et al.
Published: (2020)

"Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer"
by: Anne Pernille Harlem Dyrbekk, et al.
Published: (2023)

Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer
by: Jonathan R. Thompson, et al.
Published: (2016)

Tyrosine kinase inhibitors: new molecules in non-small cell lung cancer (EGFR AND ALK)
by: Fernando Franco, et al.
Published: (2017)

ALK1 Gene Rearranged Pulmonary Sarcomatoid Carcinoma Masquerading as Tuberculosis in a Young Male
by: Ayushi SAHAY, et al.
Published: (2021)

Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population
by: Ruiying Zhao, et al.
Published: (2021)

Case Report: ALK rearranged locally advanced lung adenocarcinoma showing inconsistent radiographic findings and pathological responses during neoadjuvant alectinib therapy
by: Peijun Cao, et al.
Published: (2023)

Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy
by: Ruihe Lin, et al.
Published: (2023)

Clinical development of RET inhibitors in RET-rearranged non-small cell lung cancer: update
by: Luis Mendoza
Published: (2018)

Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy
by: Ali R, et al.
Published: (2019)

New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib
by: Rothschild SI
Published: (2016)

ALK-TPM3 rearrangement in adult renal cell carcinoma: a case report and literature review
by: Jing Yang, et al.
Published: (2019)

Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib
by: El-Osta H, et al.
Published: (2015)

Efficacy of alectinib in comparison with lorlatinib in patients with ALK-positive non-small cell lung cancer: pharmacoeconomic study
by: A. S. Kolbin, et al.
Published: (2023)

Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors
by: Yuchun Niu, et al.
Published: (2020)

Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers
by: Tingting Jiang, et al.
Published: (2021)

Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non-Small Cell Lung Cancer
by: Dehua Liao, et al.
Published: (2022)

Characterization of an ETV6-NTRK3 rearrangement with unusual, but highly significant FISH signal pattern in a secretory carcinoma of the salivary gland: a case report
by: Florian Wagner, et al.
Published: (2021)